Linked Life Data

16080035

Source:http://linkedlifedata.com/resource/pubmed/id/16080035

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2005-8-4
pubmed:abstractText
A number of novel compounds generated much interest and discussion at the AACR Meeting in San Francisco. Among these was a novel cell cycle inhibitor from F Hoffmann-La Roche Ltd, Ro-31-7453. The synthesis and preclinical investigations conducted with this compound had not been discussed in public before the AACR meeting. Roche has quite clearly been keeping developments relating to this compound very confidential since the compound progressed as far as phase I trials before any public disclosures were made. In an interview, Dr Lars Breimer (Roche Products Ltd, Welwyn Garden City, UK), explained why Ro-31- 7453 should be generating so much interest at the AACR, and how cell cycle inhibition is proving to be an attractive target for drug development.
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:month
Jul
pubmed:issn
1369-7056
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
723-5
pubmed:year
2000
pubmed:articleTitle
AACR -91st meeting. Interview with Dr Lars Breimer.
pubmed:affiliation
Current Drugs Ltd, 34-42 Cleveland Street, London, W1P 6LB, UK. charlotte.worker@current-drugs.com
pubmed:publicationType
Journal Article